Abstract
Colon cancer is the most frequently diagnosed cancer, taking about 700,000 lives every year. In stage I, colon cancer shows the five-year survival rate higher than 90%. However, after medical therapy, there are still a group of cancer stem cells (CSCs, less than 0.1%) hard to treat. But there are no specific biomarker only presented to recognize colon-CSCs. In this study, a new microfluidic system was demonstrated to be able to select high-affinity aptamers specific to colon-CSC and colon cancer cells by performing an automated on-chip Cell-SELEX process.